PP 405
Alternative Names: PP-405Latest Information Update: 20 Aug 2024
At a glance
- Originator University of California at Los Angeles
- Developer Pelage Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Mitochondrial membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia
Most Recent Events
- 05 Jun 2024 Phase-II clinical trials in Alopecia in USA (Topical) (NCT06393452)
- 09 Mar 2024 Efficacy and pharmacokinetics data from a phase I trial in presented at the American Academy of Dermatology 2024 Annual Meeting (AAD-2024)
- 27 Feb 2024 Pelage Pharmaceuticals plans a phase IIa trial for Alopecia in mid-2024